Overview

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2030-11-01

Target enrollment:

Participant gender:

Summary

The DEPECA-1 trial is the first systematic Phase II trial to evaluate response and survival to a combination of antibody-drug conjugate enfortumab vedotin plus the PD-L1 inhibitor avelumab in patients with locally advanced and metastatic penile squamous cell carcinoma (PeCa) in the 1st line setting.

Phase:

PHASE2

Details

Lead Sponsor:

Institut fr Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators:

Astellas Pharma GmbH
Merck KGaA, Darmstadt, Germany
University Hospital Tbingen

Treatments:

avelumab
enfortumab vedotin